Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nicolas Frey

Showing results (31-40 of 55) with videos related to

Pageof 6
Sort By:
Studies in Health Technology and Informatics|August 23, 2024
Factors Influencing the Strategic Governance of EHR Interoperability: A Rapid Literature ReviewFuko Chiba, Alessia Nowak, Nicolas Frey, et al.
British Journal of Clinical Pharmacology|February 12, 2021
Population pharmacokinetic analysis of RO5459072, a low water-soluble drug exhibiting complex food-drug interactionsNicole A Kratochwil, Cordula Stillhart, Cheikh Diack, et al.
British Journal of Clinical Pharmacology|May 4, 2019
Pharmacokinetics, exposure, efficacy and safety of obinutuzumab in rituximab-refractory follicular lymphoma patients in the GADOLIN phase III studyEkaterina Gibiansky, Leonid Gibiansky, Vincent Buchheit, et al.
JMIR Medical Informatics|September 9, 2024
Alarm Management in Provisional COVID-19 Intensive Care Units: Retrospective Analysis and Recommendations for Future PandemicsMaximilian Markus Wunderlich, Nicolas Frey, Sandro Amende-Wolf, et al.
CPT: Pharmacometrics & Systems Pharmacology|September 21, 2021
Pharmacometric analyses of alectinib to facilitate approval of the optimal dose for the first-line treatment of anaplastic lymphoma kinase-positive non-small cell lung cancerJoy C Hsu, Felix Jaminion, Elena Guerini, et al.
CPT: Pharmacometrics & Systems Pharmacology|March 20, 2025
A Model-Based Approach to Evaluate Anti-Drug Antibody Impact on Drug Exposure With Biologics: A Case Example With the CD3 T-Cell Bispecific CibisatamabJavier Sanchez, Philippe B Pierrillas, Nicolas Frey, et al.
Journal of Clinical Pharmacology|September 4, 2007
An integrated model for glucose and insulin regulation in healthy volunteers and type 2 diabetic patients following intravenous glucose provocationsHanna E Silber, Petra M Jauslin, Nicolas Frey, et al.
Studies in Health Technology and Informatics|September 5, 2024
InterAgent on FHIR - Lessons Learned from Implementing an Intelligent Tutoring System with the Help of HL7 FHIRNicolas Frey, Nina Haffer, Lennart Vogelsang, et al.
British Journal of Clinical Pharmacology|July 15, 2025
Pharmacokinetic and pharmacodynamic modelling of continuous erythropoiesis receptor activator in children: A comprehensive analysis and real-world data validationSamer Mouksassi, Franz Schaefer, Bradley A Warady, et al.
Cancer Chemotherapy and Pharmacology|September 18, 2021
Population pharmacokinetic analysis of entrectinib in pediatric and adult patients with advanced/metastatic solid tumors: support of new drug application submissionMario González-Sales, Nassim Djebli, Georgina Meneses-Lorente, et al.
Pageof 6

Showing results (31-40 of 55) with videos related to

Sort By:
Pageof 6
Studies in Health Technology and Informatics|August 23, 2024
Factors Influencing the Strategic Governance of EHR Interoperability: A Rapid Literature ReviewFuko Chiba, Alessia Nowak, Nicolas Frey, et al.
British Journal of Clinical Pharmacology|February 12, 2021
Population pharmacokinetic analysis of RO5459072, a low water-soluble drug exhibiting complex food-drug interactionsNicole A Kratochwil, Cordula Stillhart, Cheikh Diack, et al.
British Journal of Clinical Pharmacology|May 4, 2019
Pharmacokinetics, exposure, efficacy and safety of obinutuzumab in rituximab-refractory follicular lymphoma patients in the GADOLIN phase III studyEkaterina Gibiansky, Leonid Gibiansky, Vincent Buchheit, et al.
JMIR Medical Informatics|September 9, 2024
Alarm Management in Provisional COVID-19 Intensive Care Units: Retrospective Analysis and Recommendations for Future PandemicsMaximilian Markus Wunderlich, Nicolas Frey, Sandro Amende-Wolf, et al.
CPT: Pharmacometrics & Systems Pharmacology|September 21, 2021
Pharmacometric analyses of alectinib to facilitate approval of the optimal dose for the first-line treatment of anaplastic lymphoma kinase-positive non-small cell lung cancerJoy C Hsu, Felix Jaminion, Elena Guerini, et al.
CPT: Pharmacometrics & Systems Pharmacology|March 20, 2025
A Model-Based Approach to Evaluate Anti-Drug Antibody Impact on Drug Exposure With Biologics: A Case Example With the CD3 T-Cell Bispecific CibisatamabJavier Sanchez, Philippe B Pierrillas, Nicolas Frey, et al.
Journal of Clinical Pharmacology|September 4, 2007
An integrated model for glucose and insulin regulation in healthy volunteers and type 2 diabetic patients following intravenous glucose provocationsHanna E Silber, Petra M Jauslin, Nicolas Frey, et al.
Studies in Health Technology and Informatics|September 5, 2024
InterAgent on FHIR - Lessons Learned from Implementing an Intelligent Tutoring System with the Help of HL7 FHIRNicolas Frey, Nina Haffer, Lennart Vogelsang, et al.
British Journal of Clinical Pharmacology|July 15, 2025
Pharmacokinetic and pharmacodynamic modelling of continuous erythropoiesis receptor activator in children: A comprehensive analysis and real-world data validationSamer Mouksassi, Franz Schaefer, Bradley A Warady, et al.
Cancer Chemotherapy and Pharmacology|September 18, 2021
Population pharmacokinetic analysis of entrectinib in pediatric and adult patients with advanced/metastatic solid tumors: support of new drug application submissionMario González-Sales, Nassim Djebli, Georgina Meneses-Lorente, et al.
Pageof 6